https://www.selleckchem.com/products/ly333531.html
althcare professionals, can be applied to improve adherence to hypertension treatment regimens in order to reduce the consequences of uncontrolled blood pressure. To evaluate the efficacy and safety outcomes of dexamethasone intravitreal implant in patients with Stage 3A Coats' disease. A consecutive case series of adult Coats' disease managed with or without intravitreal dexamethasone implant (Ozurdex®, Allergan Inc., Irvine, California, USA) injection was retrospectively evaluated. The medical records of all included patients with a
Like
Comment
Share
